


PRODUCT INFORMATION



Zonisamide

Item No. 24183

CAS Registry No.: 68291-97-4
Formal Name: 1,2-benzisoxazole-3-methanesulfonamide
Synonyms: CI-912, PD 110843
MF: C₈H₈N₂O₃S
FW: 212.2
Purity: ≥98%
UV/Vis.: λ_{max}: 238, 284 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Zonisamide is supplied as a crystalline solid. A stock solution may be made by dissolving the zonisamide in the solvent of choice. Zonisamide is soluble in the organic solvent DMSO, which should be purged with an inert gas. It is also soluble in water. The solubility of zonisamide in DMSO and water is <100 and <10 mM, respectively. We do not recommend storing the aqueous solution for more than one day.

Description

Zonisamide is a broad-spectrum sulfonamide antiepileptic agent.¹ It selectively blocks the repeated firing of sodium channels (IC₅₀ = 2 µg/ml) at low concentrations in mouse embryo spinal cord neurons, and it blocks spontaneous channel firing at concentrations above 10 µg/ml.² In rat cerebral cortex neurons, zonisamide (1-1000 µM) dose-dependently blocks T-type calcium channels with a maximum reduction of 60% of the calcium current.³ Zonisamide inhibits recombinant *H. pylori* carbonic anhydrase (CA) and human CA isoforms I, II, and V with K_i values of 218, 56, 35, and 21 nM, respectively.^{4,5} Zonisamide has anticonvulsant activity in rats, rabbits, dogs, and mice with a potency similar to phenobarbital (Item No. 9001494) and carbamazepine in maximal electroshock seizure (MES) models.¹ In mice, it has anticonvulsant activity against MES and pentylenetetrazole-induced maximal and minimal seizures with median effective doses of 19.6, 9.3, and >500 mg/kg, respectively. Zonisamide (10-100 mg/kg, p.o.) dose-dependently prevents reduction of dopamine (Item No. 21992), homovanillic acid (HVA), and dihydroxyphenyl acetic acid (DOPAC) levels and the elevation of the dopamine turnover rate induced by MPTP in mouse striatum. Formulations containing zonisamide have been used in the treatment of partial seizures in adults with epilepsy.

References

1. Masuda, Y., Ishizaki, M., and Shimizu, M. *CNS Drug Rev.* **4(4)**, 341-360 (1998).
2. Rock, D.M., Macdonald, R.L., and Taylor, C.P. *Epilepsy Res.* **3(2)**, 138-143 (1989).
3. Suzuki, S., Kawakami, K., Nishimura, S., et al. *Epilepsy Res.* **12(1)**, 21-27 (1992).
4. Nishimori, I., Vullo, D., Minakuchi, T., et al. *Bioorg. Med. Chem. Lett.* **16(8)**, 2182-2188 (2006).
5. De Simone, G., Di Fiore, A., Menchise, V., et al. *Bioorg. Med. Chem. Lett.* **15(9)**, 2315-2320 (2005).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/05/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM